Is Rulemaking Old Medicine at the FDA?

DSpace/Manakin Repository

dc.contributor.advisor	Hutt, Peter Barton	en_US
dc.contributor.author	Carey, John C.	en_US
dc.date.accessioned	2012-06-07T20:30:54Z
dc.date.issued	1997	en_US
dc.identifier.citation	Is Rulemaking Old Medicine at the FDA? (1997 Third Year Paper)	en
dc.identifier.uri	http://nrs.harvard.edu/urn-3:HUL.InstRepos:8852158
dc.description.abstract	The first three parts of this paper describe the major burdens placed on agency rulemaking by each branch of the government over the past thirty years, with specific focus on the burdens that presently affect FDA rulemaking. Part V then analyzes the effect those burdens have had on FDA rulemaking. The analysis will demonstrate that the additional rulemaking requirements likely act to deter rulemaking at the agency. In conclusion, Part VI briefly discusses the type of policymaking in which FDA currently engages as an alternative to rulemaking and describes further research to be done regarding that method of FDA policymaking.	en
dc.language.iso	en_US	en
dash.license	LAA	en_US
dc.subject	Food and Drug Law	en
dc.subject	rules	en
dc.subject	rulemaking procedures	en
dc.subject	rulemaking processes	en
dc.title	Is Rulemaking Old Medicine at the FDA?	en
dc.type	Paper (for course/seminar/workshop)	en_US
dc.date.available	2012-06-07T20:30:54Z